Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | HINT1 | P49773 | 5/20 | 0.51 |
| ▸ | NT5E | P21589 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259226 | 1.00 | ADORA2A (0.52) | ADORA2AHINT1NT5EHPGDGSK3A | |
| SCHEMBL16918687 | 0.92 | ADORA2A (0.52) | ADORA2AHINT1NT5EHPGDGSK3A | |
| SCHEMBL13483535 | 0.90 | HINT1 (0.52) | ADORA2AHINT1NT5EHPGDGSK3A | |
| SCHEMBL18744136 | 0.90 | ADORA2A (0.50) | ADORA2AHINT1NT5EHPGDGSK3A | |
| SCHEMBL16125299 | 0.90 | HINT1 (0.49) | ADORA2AHINT1NT5EHPGDGSK3A | |
| SCHEMBL13482963 | 0.90 | NT5E (0.51) | ADORA2AHINT1NT5EHPGDGSK3A | |
| SCHEMBL23171224 | 0.89 | HINT1 (0.51) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL15788412 | 0.89 | HINT1 (0.51) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL15643491 | 0.89 | HINT1 (0.51) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL17232109 | 0.89 | ADORA2A (0.48) | ADORA2ANT5EADORA3ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928876-B1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014088923-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ADORA2A 645/4885HINT1 4559/4885NT5E 586/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ADORA2A 645/4885HINT1 4559/4885NT5E 586/4885 |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | ADORA2A 353/4885HINT1 1013/4885NT5E 607/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ADORA2A 645/4885HINT1 4559/4885NT5E 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.